Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients
published in: Experimental and Clinical Endocrinology and Diabetes
date of publication: 2016-03-29
main subject: type-1 diabetes
Cites articles
There is nothing here
Article - wd:Q40112229